10:29 AM EST - Numinus Wellness Inc. : Congratulates the Multidisciplinary Association of Psychedelics Studies for its submission of a new drug application to the U.S. Food and Drug Administration for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider. Numinus Wellness Inc.
shares T.NUMI are trading down $0.01 at $0.11.
